Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer

(2016) Linghua Chen et al.   Immunotherapy

Current Status of Immunotherapy Treatments for Pancreatic Cancer

(2016) Cristina Jimenez-Luna et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Circulating protein and antibody biomarker for personalized cancer immunotherapy

(2016) Jianda Yuan   Journal for ImmunoTherapy of Cancer

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

(2015) Vincent J. Picozzi et al.   EUROPEAN JOURNAL OF CANCER

Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell

(2015) Jiang Chen et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer

(2014) S. Koido et al.   CLINICAL CANCER RESEARCH

Manipulating immune cells for adoptive immunotherapy of cancer

(2014) Phillip K Darcy et al.   CURRENT OPINION IN IMMUNOLOGY

Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis

(2014) Zheng-Xu Wang et al.   CYTOTHERAPY

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

(2014) Sumiyuki Nishida et al.   JOURNAL OF IMMUNOTHERAPY

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

(2014) Gary Middleton et al.   LANCET ONCOLOGY

Current advances in immunotherapy for pancreatic cancer

(2013) Jennifer N. Uram et al.   CURRENT PROBLEMS IN CANCER

Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4+T cells

(2013) Philippa Hillyer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer

(2013) Nobuaki Suzuki et al.   JOURNAL OF IMMUNOTHERAPY

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

(2013) Shingo Asahara et al.   Journal of Translational Medicine

A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

(2013) SHIGERU YUTANI et al.   ONCOLOGY REPORTS

Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma

(2013) Kyong Joo Lee et al.   YONSEI MEDICAL JOURNAL

Tumor microenvironment and lymphocyte infiltration

(2012) Gwendoline Rahir et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients

(2012) Hidekazu Kameshima et al.   CANCER SCIENCE

Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial

(2012) Boris Kubuschok et al.   HUMAN GENE THERAPY

Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study

(2012) Ying Qiu et al.   International Journal of Clinical Oncology

Pancreatic adenocarcinoma

(2012) G. Bond-Smith et al.   BMJ-British Medical Journal

Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients

(2011) Hisahito Endo et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031

(2010) V. J. Picozzi et al.   ANNALS OF ONCOLOGY

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

(2010) Sara Mariucci et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

(2009) Asma Sultana et al.   BMC CANCER

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

(2009) Sant P Chawla et al.   MOLECULAR THERAPY

The Immunogenicity of the hTERT540-548 Peptide in Cancer

(2008) L. Wenandy et al.   CLINICAL CANCER RESEARCH